Clinical trial
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
NCT00099736 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00099736 |
|---|---|
| Title | Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant |
| Official title | Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Transplantation |
| Intervention type | Drug |
| Interventions | FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids |
| Enrollment | 696 |
| Start date | May 7, 2003 |
| Primary completion | Sep 19, 2005 |
| Completion | Sep 19, 2005 |
| First posted | Dec 20, 2004 |
| Last update posted | Aug 22, 2017 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: